A recent study used CRISPR to validate the importance of a SE near GATA2 in chronic myeloid leukemia by demonstrating it is responsible for 80% of GATA2 expression [22]. This evidence concerns the gene GATA2 and chronic myelogenous leukemia, BCR-ABL1 positive.